Pharma Business Week articles from November 2003

Pharma Business Week archives from November 2003

Liprostin human clinical trials to commence.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Endovasc, Inc., (EVSC), an early-stage drug development company that pioneers new cardiovascular and metabolic drug therapies, announced that it has received approval from the Republic of Georgia's...

Drug may protect cancer and AIDS patients from side effects.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- A drug developed to relieve one of the major side effects of pain therapy for cancer patients may offer an added benefit for AIDS patients, researchers from the University of Chicago and the Children's...

FDA grants anti-CD4 drug fast-track status for the treatment of HIV-1.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Tanox, Inc., (TNOX) announced that the U.S. Food and Drug Administration (FDA) has granted fast-track status to TNX-355 for the treatment of patients with human-immunodeficiency virus 1 (HIV-1)...

Initiative provides investigational agent for eligible patients for free.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- In just over a year, 1000 patients in the United States diagnosed with malignant mesothelioma - an asbestos-related cancer - have received Eli Lilly and Company's investigational drug Alimta...

Ohio company wins NIH contract to manufacture Parvovirus vaccine.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Meridian Bioscience, Inc., (VIVO) of Cincinnati, Ohio, has been awarded a contract to manufacture clinical-grade recombinant-protein Parvovirus-B19 vaccine for the U.S. National Institutes of Health....

Study: Med-eMonitor improves medication compliance in those with schizophrenia.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- InforMedix, Inc., (IFMX) reported that a U.S. National Institutes of Health-sponsored study of patients with chronic schizophrenia demonstrated its Med-eMonitor, a computerized monitoring and compliance...

Tri-Nasal Nasal Spray acquired from Muro Pharmaceutical.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Collegium Pharmaceutical, Inc., a closely held specialty pharmaceutical company, announced that it has acquired from Muro Pharmaceutical, Inc., all rights to Tri-Nasal (triamcinolone acetonide, USP)...

Biologic marker specific for the diagnosis of Alzheimer disease.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Berlex Pharmaceuticals, a U.S. affiliate of Schering AG Germany (SHR), announced that it has discovered that a receptor protein molecule, CCR1, that is usually found on the surface of white blood cells...

Research program funded for study of RNAi technology in ALS.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- CytRx Corporation (CYTR) announced that it has agreed to fund a sponsored research program at the University of Massachusetts Medical School (UMMS) for the use of RNAi gene silencing technology in the...

Rheumatoid arthritis treatment studied in phase II trial.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Regeneron Pharmaceuticals, Inc., (REGN) announced that the company's IL-1 Trap demonstrated evidence of efficacy and safety in patients with rheumatoid arthritis (RA) in a phase II dose-ranging study in...

Phase II study initiated to evaluate recombinant alpha 1-antitrypsin gel.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- ProMetic Life Sciences (TSX: PLI) and Arriva Pharmaceuticals, Inc., announced that their joint venture company, Arriva-ProMetic, Inc., (JV), has opened a phase II clinical study to evaluate its lead...

Two phase IIa trials initiated in dermatology.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Encysive Pharmaceuticals (ENCY) announced that its majority-owned German affiliate, Revotar Biopharmaceuticals AG, initiated two double-blind, placebo, and standard drug controlled phase IIa clinical...

Services launched for biorepository management.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Ardais Corporation announced the availability of its Biomaterials and Information for Genomic Research (BIGR) Biospecimen Management System (BMS), a comprehensive set of services and licenses that...

Tissue to be used to determine genetic cause of cancer.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Asterand, the Detroit-based human tissue bank, is re-examining research materials and data donated over 30 years ago for new clues to the genetic causes of breast cancer. "October is breast cancer...

Biotech-based anticancer therapies becoming more prevalent.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- New figures released today by Pharmaprojects show that a quarter of all anti-cancer therapies in development are based on biotechnology. Pharmaprojects analyzed the number of biotechnology products...

MDdatacor hits milestone, with 2 million cardiology patients in database.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- MDdatacor, inc., announced at Barnett International's eighth annual Strategies to Maximize Patient Recruitment Conference that it has accumulated longitudinal medical data for more than 2 million...

NIH grant to be used for development of stem cell treatment.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Aastrom Biosciences, Inc., (ASTM) announced that it has received a $100,000 Phase I Small Business Innovation Research grant from the U.S. National Institutes of Health (NIH) to develop a bone marrow...

Alliance to develop RNAi compounds, gene regulation research.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Acacia Research Corporation (CBMX, ACTG) announced that CombiMatrix is collaborating with researchers at the Seattle Biomedical Research Institute (SBRI). The collaboration was formed to conduct a...

Alliance to expand immunoassay portfolio.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Beckman Coulter, Inc., (BEC) announced that they have entered into an agreement with R&D Systems, a wholly owned subsidiary of Techne Corporation (TECH). Effective immediately, the non-exclusive,...

Alliance to focus on discovery of new biomarkers of inflammatory disease.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- BioVisioN AG, Hannover, and the international pharmaceutical company AstraZeneca have signed a collaboration agreement. The collaboration will focus on the discovery of new biomarkers of...

Amended agreement signed to sell Eligix HDM System.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- BioTransplant, Inc., announced that it has entered into an amended agreement relating to the sale of its Eligix HDM Cell Separation System to Miltenyi Biotec GmbH. Because certain of the biological...

Commercialization agreement signed for home nebulizer.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Aerogen, Inc., (AEGN) and Medical Industries America, Inc., (MIA) announced that they have entered into an agreement for manufacturing and marketing of the Aeroneb Go Nebulizer (Aeroneb Go), which...

Company alliance targets development of new transfection technology.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Swedish biotech tools company Cellectricon announced that it has licensed Axon Instruments (Union City, California) to have sole access to Cellectricon's patented electroporation technology. Under...

Gene regulation database licensed.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Cognia Corporation, developers and distributors of information products for drug discovery, announced that research groups at Pfizer, Inc., and Chiron, Inc., licensed Transfac Professional. ...

Promotion agreement signed with Baxter for vaccine manufacturing services.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Althea Technologies, Inc., a provider of gene-based manufacturing and testing services to accelerate drug development, announced that it has entered into an agreement with Baxter Healthcare Corporation...

Research to assess factors affecting siRNA for gene silencing.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Dharmacon, Inc., a supplier of RNA and RNA interference (RNAi) research products, announced that it has entered into a collaboration with Rosetta Inpharmatics, LLC, a wholly owned subsidiary of Merck &...

New drug to be marketed in U.S. to treat congestive heart failure.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Pfizer, Inc., has received approval from the U.S. Food and Drug Administration (FDA) to market Inspra (eplerenone tablets) for the treatment of congestive heart failure (CHF) in patients who have had a...

Chemistry-driven drug discovery company changes name.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- ChemCodes, Inc., announced its name change to Nuada Pharmaceuticals, Inc. This change is part of the overall plan of realigning of its business mission and growth to focus on discovery of small...

FemOne announces name change, new symbol.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- FemOne, Inc., (FEMOV), formerly New Paltz Capital Corp. (NPZC), a Carlsbad, California-based, direct selling nutrition, skincare, and cosmetics company with distribution in the United States and Canada,...

Crohn disease drug therapies will nearly double to $1.2 billion in 2012.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Decision Resources, Inc., finds that sales of Crohn disease (CD) drug therapies will increase from $713 million in 2002 to nearly $1.2 billion in 2012. According to a new Pharmacor study entitled...

Patient simulator improves performance of clinical trial coordinators.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Duke University Medical Center researchers have demonstrated that training research coordinators on a human simulator prior to a complex clinical trial can significantly improve the coordinators'...

Human Epigenome Project to follow E.U.-pilot study.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Epigenomics AG and The Wellcome Trust Sanger Institute announced an agreement to fund and carry out the first phase of the Human Epigenome Project (HEP). The HEP will identify and describe sites in...

Noveon expands thermoplastic-urethane product line.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Noveon has purchased certain assets of Thermedics Polymer (Thermedics), a manufacturer of thermoplastic polyurethane (TPU), from VIASYS Healthcare, Inc. This acquisition will expand Noveon's Estane...

U.S. FDA issues approval letter for insulin analog to treat diabetes.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Novo Nordisk A/S (NVO) has received an approvable letter from the U.S. Food and Drug Administration (FDA) for insulin detemir, a long-acting insulin analog for the treatment of diabetes. In the...

Moore Medical obtains rights to distribute medical products.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Moore Medical Corp. (MMD) has obtained the rights to distribute Midmark Corp.'s line of medical products, including power and manual exam tables, specialty tables and chairs, sterilizers, diagnostic...

Agreement to sell gastrointestinal products signed.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Aventis announced it has agreed to sell Axcan Pharma, Inc., the North American rights to three Aventis gastrointestinal products. Under the terms of the agreement, Axcan will acquire Carafate and...

BioMEMS maker and MicroCHIPS expand strategic R&D partnership.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Micralyne, Inc., and MicroCHIPS, Inc., announced that they have expanded the scope of their work together for the development of MicroCHIPS' innovative drug-delivery and biosensing devices. ...

New product candidate to combine SEPA technology, Novartis compound.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- MacroChem Corp. (MCHM) announced that it is engaged in a collaboration to evaluate a novel product candidate combining MacroChem's patented SEPA drug-absorption-enhancement technology with an...

Rights acquired to new aerosol inhalation device.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Bayer Biological Products (BP) announced the signing of a deal with Inamed GmbH (Gemuenden, Germany) for exclusive use of its new advanced inhalation technology for the dosing of alpha-1 antitrypsin...

New medicines at risk from biodiversity loss.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Three scientists warn that biodiversity loss could have devastating consequences for drug discovery and the development of new medicines. "Tropical cone snails may contain the largest and most...

Pharmaceutical company developing products to fight E. coli contamination.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Nymox Pharmaceutical Corporation (NYMX) is taking two approaches to address the serious public health problem posed by the contamination of meat and other food and drink products by potentially deadly...

Biotech firm engages provider of investment banking services.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- American Oriental Bioengineering, Inc., (AOBO) announced that the company has engaged Westminster Securities Corporation to provide investment banking services. Westminster Securities will assist...

Biotech firm raises $56M in series B financing.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Critical Therapeutics, Inc., (CTI), a private biopharmaceutical company that discovers and develops novel therapies for critical care medicine, announced it has closed a $56 million Series B financing....

Cancer vaccine company completes UKP 17M financing.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- BioVex, Ltd., announced the completion of a UKP 17 million (U.S. $28 million) private placement. The placement was led by Scottish Equity Partners (U.K.). Other new investors participating in the...

Immune system therapy developer announces conversion of debt.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Cel-Sci Corp. (CVM) announced that all of the remaining outstanding debentures from its debt financing with two institutional investors have been converted into shares of Cel-Sci common stock. This...

Oncology company's resale registration statement declared effective by SEC.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Cytogen Corporation (CYTO), a product driven, oncology-focused biopharmaceutical company, announced that the U.S. Securities and Exchange Commission (SEC) has declared effective the resale registration...

Pharmaceutical company amends guidance based on merger activity.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Cima-Labs, Inc., announced that it is updating its guidance for the third quarter and full year 2003. Third-quarter revenues are expected to be within the company's previously announced guidance...

Pharmaceutical company amends stockholders agreement.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Arena Pharmaceuticals, Inc., (ARNA) announced that the stockholders agreement dated as of January 17, 2003, with its largest stockholder, Biotechnology Value Fund, L.P. and certain related entities...

Pharmaceutical company announces public offering of 5.6M shares.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Cubist Pharmaceuticals, Inc., (CBST) announced its intention to publicly offer 5.6 million shares of its common stock pursuant to its effective "shelf" registration statement previously filed with the...

Pharmaceutical company anticipates stronger-than-expected third quarter.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Bradley Pharmaceuticals, Inc., (BDY) announced that it anticipates earnings per diluted share for the third quarter 2003 will meet or exceed a range of $0.34 to $0.36, an approximately 17% to 24%...

Pharmaceutical company completes $40.5M financing.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Akorn, Inc., (AKRN) announced that it has completed its $40.5 million financing. On September 25, 2003, the company announced that it had entered into a preferred stock and note purchase agreement...

Pharmaceutical company secures $57M in a senior credit facility.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- ESP Pharma, Inc., announced that it has closed a $57 million senior credit facility with a syndicate of lenders. This, in combination with prior Series A and B funding rounds, represents an...

Pharmaceutical company sells common stock.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- CollaGenex Pharmaceuticals, Inc., (CGPI) announced that Marquette Venture Partners II, L.P., and OCM Principal Opportunities Fund, L.P., have separately entered into agreements with certain...

Pharmaceutical firm developing wound healing gel announces $2.5M investments.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Cytomedix, Inc., (CYME) announced that it has closed a private offering of its common stock. The private offering generated $2,499,000 in gross proceeds. The proceeds of the offering will be used...

Pharmaceutical firm prices IPO.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Acusphere, Inc., (ACUS) announced the pricing of its initial public offering of 3,750,000 shares of its common stock at $14.00 per share, before underwriting discounts and commissions. The offering...

Vaccine maker files shelf registration statement for 15M shares.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Avant Immunotherapeutics, Inc., (AVAN) announced the filing of a shelf registration on Form S-3 with the U.S. Securities and Exchange Commission (SEC). Once declared effective by the SEC, the shelf...

Drug discovery company raises $15 million in first close of equity financing.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Nuevolution A/S has raised US$15 million in the first closing of a series B equity financing. This second round of financing was led by Scandinavian Life Science Venture, and brings to US$24...

Companies form research collaboration to develop novel high-content drug screens.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Cellular Genomics, Inc., (CGI), a chemical genetics based biopharmaceutical company, announced that it has established a research collaboration with Affymetrix, Inc. In the collaboration, CGI will...

Agreement terminated with Amersham.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Epoch Biosciences, Inc., (EBIO), a provider of proprietary products that accelerate genomic analysis, announced that the company had terminated a distribution and licensing agreement with Amersham...

Data released for 120,000 validated SNPs into public domain.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Affymetrix, Inc., (AFFX) released genotype data for 120,000 validated single nucleotide polymorphisms (SNPs) selected from both public SNP databases and the proprietary SNP database developed by...

China clinical trials completed for antibody tests.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Calypte Biomedical Corporation (CYPT), the developer and marketer of the only two U.S. Food and Drug Administration (FDA) approved HIV-1 antibody tests that can be used on urine samples, as well as an...

MedPointe expands sales force to, among other duties, promote ZOMIG.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- MedPointe, Inc., has created three new sales forces and is in the process of recruiting 260 additional experienced pharmaceutical-sales representatives. The company is on track to fully staff these...

Healthcare plan educates members about proton-pump inhibitors.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- As part of a long-standing commitment to educating its members and helping them maximize available benefits, Aetna will provide approximately 100,000 pharmacy members with educational information about...

Not approvable letter issued for Helicide.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Axcan Pharma, Inc., has announced that the U.S. Food and Drug Administration (FDA) has determined that the New Drug Application (NDA) that Axcan re-submitted for Helicide for the eradication of...

Pharmaceutical company files for GM-CSF approval in Canada.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Cangene Corporation (CNJ) announced that it has filed a Canadian New Drug Submission for Leucotropin, a protein known as GM-CSF. The submission seeks approval from the Biologics and Genetic...

Adjuvant licensed for the development of HIV vaccine.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- The Immune Response Corporation (IMNR) and Hybridon, Inc., (HYBN) have entered into a license agreement for the use of Amplivax as an adjuvant in the development of a novel vaccine candidate for the...

Combination hormone therapy does not benefit patients.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Combining two hormone therapies to treat the psychological effects of hypothyroidism may not be more effective than using a single therapy, according to new research articles published in the Journal of...

Orphan drug status granted for OGP.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- The Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on the designation of the product OGP (10-14)L (H-Tyrosine-Glycine-Phenilalanine-Glycine-Glycine-OH) as an orphan drug for...

Healthcare professionals updated on new CDC hand hygiene guidelines.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- 3M Health Care has sponsored a new video to make it easier for healthcare professionals to update their procedures in light of the new hand hygiene guidelines issued recently by the U.S. Centers for...

Drug development discontinued due to unsatisfactory preliminary data.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Xoma Ltd. has discontinued development of MLN2201, a humanized monoclonal antibody being developed for conditions related to inflammation of the heart and blood vessels. MLN2201 was one of two...

Biochip company starts commercial shipment of SealChip16.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Biochip and cell biology solution provider Aviva Biosciences Corp. announced that it has started the commercial shipment of SealChip16, a single-use disposable product that performs automated high...

Lawsuit settlement results in unlimited licensing rights.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Nutra Pharma Corp. (NPHC) has settled its lawsuit against Bio Therapeutics, Inc., whereby the settlement provides Nutra Pharma Corp. the unlimited licensing rights to critical intellectual property of...

Canadian marketing rights licensed for non-prescription stimulant product.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Xanodyne Pharmacal, Inc., has licensed Canadian distribution and marketing rights for its non-prescription stimulant product Lucidex (enteric coated caffeine, 100 mg) to Pharmascience, Inc. Lucidex...

European orphan drug designation granted for Thymitaq.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Eximias Pharmaceutical Corporation announced that it has received Orphan Medicinal Product designation from the Commission of the European Communities, based on the favorable opinion of the European...

Once-a-day "smart drug" testing expands.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- It is a drug suffused in promise, a next-generation therapy that has shown glimmers of powerful potential. Iressa is the kind of treatment that oncologists dream of - a pill that can be swallowed once a...

Communicating clinical trial results drives product uptake.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Executives at top pharmaceutical companies consider factors such as audience receptivity and location when communicating clinical study results to consumers, according to a newly released study by...

HealthTrak identifies Rx purchasing behaviors and patterns.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Marketing Technology Solutions (MTS) announced the availability of MTS HealthTrak; according to the company, it is the largest consumer-health longitudinal panel ever conducted. Sourced from a...

Portion of pharmaceutical companies' revenue derived from licensing.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Commercialization offers the best hope for continued pharmaceutical pipeline growth, according to a new study by Cutting Edge Information. In recent years, first string pharma companies answered...

Agency assigned to handle StaphVAX and WinRho SDF.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Integrity Healthcare Communications, the newest agency in the HealthSTAR Communications network, has been assigned several projects by Nabi Biopharmaceuticals (NABI). Nabi Biopharmaceuticals, which...

Market research budgets quadruple as new products near launch.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Pharmaceutical market research budgets more than quadruple when developing products advance from phase II to phase III, according to a recent early-stage marketing study from pharmaceutical intelligence...

Medical service liaisons serve as key link in pharmaceutical alliances.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Pharmaceutical companies spend up to $200,000 hiring consultants to brainstorm creative brand names for new drugs, according to a recent study by pharmaceutical intelligence firm Cutting Edge...

Report: When launching blockbusters, early investments fuel maximum impact.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- In order to boost market uptake to a maximum first-year peak, successful pharmaceutical executives ramp up investments in prelaunch-marketing activities, according to a study from...

Panel to examine intravenous medication harm prevention.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- Alaris Medical Systems, Inc., (AMI), provider of practical solutions for medication safety, announced its sponsorship of an industry-wide workgroup to examine the potential for harm from intravenous...

Phase III clinical trial of Bio-E-Gel initiated.
November 3, 2003... 2003 NOV 3 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals, Inc., (BPA) announced that it has initiated a pivotal phase III clinical trial of Bio-E-Gel (estradiol topical gel) for the treatment of moderate-to-severe hot flushes and...